Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 360 clinical trials
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations

The AML18 Trial will evaluate several relevant therapeutic questions in Acute Myeloid Leukaemia (AML), as defined by the WHO, and High Risk Myelodysplastic Syndrome. The trial is primarily designed for patients over 60 years considered fit for an intensive chemotherapeutic approach, but younger patients who may not be considered suitable …

vosaroxin
azacitidine
cytarabine
mylotarg
ara-c
  • 381 views
  • 23 Jan, 2021
  • 83 locations
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

Primary objective of this open label, two-arm, multicenter, multinational, randomized trial is to compare anti-leukemic activity of allogeneic stem cell transplantation for patients with acute leukemia in complete remission between a 10/10 HLA matched unrelated donor and a haploidentical donor. The hypothesis: Haploidentical stem cell transplantation with post cyclophosphamide induces …

cell transplantation
cyclophosphamide
remission
acute leukemia
myeloid leukemia
  • 1 views
  • 03 May, 2021
  • 24 locations
A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following subjects: Subjects receiving luspatercept on a parent protocol at the time of their transition to the rollover study, who tolerate the protocol-prescribed regimen in the parent trial and, in the opinion of the …

growth factor
ace-536
hysterectomy
cancer
luspatercept
  • 83 views
  • 27 Jan, 2021
  • 125 locations
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT

Treatment options for older adults with Acute Myeloid Leukaemia (AML) and Myelodysplasia (MDS) are limited. Although stem cell transplantation remains one of the most effective treatments it is

fludarabine
cell transplantation
hla-a
thiotepa
myelodysplasia
  • 0 views
  • 24 Jan, 2021
  • 1 location
A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants

very high risk myelodysplastic syndrome (MDS) who are not suitable for treatment with intensive chemotherapy or a stem-cell transplant (HSCT).

cell transplantation
azacitidine
  • 0 views
  • 15 Sep, 2021
  • 9 locations
Study of ASTX727 vs IV Decitabine in MDS CMML and AML

Multicenter, randomized, open-label, crossover PK study of ASTX727 versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily5 in Cycle 1 followed by IV decitabine 20 mg/m^2 Daily5 in Cycle 2, or the converse order. After completion of …

decitabine
chronic myelomonocytic leukemia
anemia
induction chemotherapy
myelomonocytic leukemia
  • 269 views
  • 27 Jan, 2021
  • 93 locations
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

The primary objective of this study now is to assess the anti-neoplastic activity of flotetuzumab in patients with PIF/ER AML, as determined by the proportion of patients who achieve complete remission (CR) or complete remission with partial hematologic recovery (CRh).

anthracyclines
azacitidine
cytarabine
leukemia
myeloid leukemia
  • 116 views
  • 03 Jun, 2021
  • 41 locations
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who have received standard therapy

blast cells
IDH2
hematologic malignancy
  • 0 views
  • 16 Sep, 2021
  • 47 locations
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Phase 1 Part (Complete): Open-label, sequential dose escalation study of CPI-0610 in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis. Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with Myelofibrosis. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) …

growth factor
janus kinase inhibitor
platelet count
myelofibrosis
blast cells
  • 242 views
  • 04 Sep, 2021
  • 60 locations
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by …

bone marrow procedure
transient myeloproliferative disorder
cytopenia
etoposide
daunorubicin
  • 153 views
  • 03 Sep, 2021
  • 142 locations